2021 CMSC Annual Meeting

Tag: LLC

Poster-Quality of Life and Outcomes

Trends in Absence Time and Payments Due to Long- and Short-Term Disability and Workers’ Compensation for Employees with Multiple Sclerosis

Background: Employers offer a variety of absence benefits. It is unknown how benefit design impacts the use of the benefits, the length of...

Read More

Poster-Quality of Life and Outcomes

A Real-World Study Characterizing Symptoms and Impacts of Fatigue in US Adults with Relapsing Multiple Sclerosis Using a Novel Disease Specific Scale

Background: Fatigue is among the most frequent and disabling symptoms in RMS patients. Objectives: To measure multiple sclerosis (MS)...

Read More

Poster-Quality of Life and Outcomes

Differences in Expected Number of Clinical Management Events before and during Treatment with Sphingosine-1-Phosphate Receptor Modulators for Multiple Sclerosis

Background: Sphingosine-1-phosphate receptor modulators (S1Ps), a class of oral disease-modifying therapies (DMTs) for multiple sclerosis...

Read More

Poster-Quality of Life and Outcomes

Assessing Presence of MS-Related Symptoms As a Proxy for Disease Severity in Multiple Sclerosis Using Administrative Claims Data

Background: Healthcare claims data lack clinically relevant variables such as disease severity. Objectives: Assess multiple sclerosis...

Read More

Poster-Quality of Life and Outcomes

Clinical and Economic Impact of Employees Who Are Care Partners of Patients with Multiple Sclerosis

Background: Historically, there has been limited research on care partners of patients with multiple sclerosis (MS). Employers, health care...

Read More

Poster-Neuroimmunology and disease models

Comparing Infection-Related Outcomes By Sex in Patients with Multiple Sclerosis and Matched Controls Using Administrative Claims Data

Background: Few population-level sex-based risk estimates of specific infections exist for US patients with multiple sclerosis (MS)....

Read More

Poster-Epidemiology and Genetics

Baseline Cognitive Impairment in Relapsing-Remitting Multiple Sclerosis Patients Enrolling in the US-Based Corrona MS Registry

Background: An estimated 85% of persons with multiple sclerosis (MS) present with relapsing-remitting (RRMS) disease. There are few large...

Read More

Poster-Disease-modifying Therapy

Evaluating Perceptions of Ofatumumab in Multiple Sclerosis Via Social Media Listening – Early 3 Months Post Approval Data

Background: Superior efficacy and safety of ofatumumab were demonstrated in Phase III ASCLEPIOS trials. Objectives: The social media...

Read More

Platform-Disease Management

Optical Coherence Tomography As a Biomarker for Multiple Sclerosis Studies

Background: Optic Neuritis occurs in about 20% of MS patients as the initial symptom. Objectives: To assess the clinical utility of optical...

Read More